Citi raised its target after Sanofi's recent performance, and Dupixent helped third-quarter results beat expectations. Pipeline drugs are expected to bring only 14% of 2025 peak sales, and rivals may slow Dupixent growth from 32% in 2026 to 12% in 2027.
The higher target reflects Citi's view of Sanofi's recent performance, and Dupixent helped third-quarter results beat expectations. But Sanofi may need acquisitions to fill gaps in its drug pipeline. New rivals could also slow growth in its biggest product. Those concerns outweigh the positive results and higher target.
AstraZeneca is named among possible future competitors to Sanofi's Dupixent. The story gives no confirmed sales gain or other change for AstraZeneca, so its outlook is unchanged.
Pfizer is named among possible future competitors to Sanofi's Dupixent. The story gives no confirmed sales gain or other change for Pfizer, so its outlook is unchanged.
AbbVie is named among possible future competitors to Sanofi's Dupixent. The story gives no confirmed sales gain or other change for AbbVie, so its outlook is unchanged.
Follow Sanofi (SNY) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for SNY